EMA Publishes Plan to Deal with Supply Shortages - - BioPharm International

ADVERTISEMENT

EMA Publishes Plan to Deal with Supply Shortages



The European Medicines Agency has published a plan to help Europe’s regulatory network prevent, mitigate, and manage shortages of important medicines following manufacturing problems.

Shortages of medicines arising from unforeseen disruptions within manufacturing processes, such as GMP compliance issues, have increased in recent years. However, experience from these shortages has enabled the EMA to identify several short- and medium-term actions that will help to deal with future occurrences. These actions are outlined in the EMA’s reflection paper on medicinal product supply shortages caused by manufacturing/Good Manufacturing Practice Compliance problems.

Some of the actions being taken in the short term include, among others:

  • Creating a public catalogue of current shortages
  • Establishing standard operating procedures for handling reports of shortages
  • Develop international cooperation to enable information sharing for specific shortages and on best practices on risk management and prevention strategies
  • Raise the awareness of the impact of medicine shortages and stimulate industry reaction and improvements.

In the medium term, the EMA hopes to:

  • Facilitate risk–benefit evaluation where risk shortage has to be balanced with potential risk because of the presence of a product defect.
  • Require all marketing authorization holders to submit a risk analysis of their manufacturing processes to identify weaknesses, and contingency plans to strengthen these points.
  • Investigate processes that could be used to measure the impact of medicines in patients.
  • Promote better and proactive risk management by marketing authorization holders.

According to EMA, several trends have converged to increase the number of medicines’ shortage. One of the major contributing factors is the globalization of supply chains and manufacturing networks.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines

Click here